Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 1.610
Electron. j. biotechnol ; 52: 21-29, July. 2021. ilus, tab, graf
Article in English | LILACS | ID: biblio-1283484


BACKGROUND: Super-paramagnetic iron oxide nanoparticles (SPION) contain a chemotherapeutic drug and are regarded as a promising technique for improving targeted delivery into cancer cells. RESULTS: In this study, the fabrication of 5-fluorouracil (5-FU) was investigated with loaded Dextran (DEXSPION) using the co-precipitation technique and conjugated by folate (FA). These nanoparticles (NPs) were employed as carriers and anticancer compounds against liver cancer cells in vitro. Structural, magnetic, morphological characterization, size, and drug loading activities of the obtained FA-DEX-5-FUSPION NPs were checked using FTIR, VSM, FESEM, TEM, DLS, and zeta potential techniques. The cellular toxicity effect of FA-DEX-5-FU-SPION NPs was evaluated using the MTT test on liver cancer (SNU-423) and healthy cells (LO2). Furthermore, the apoptosis measurement and the expression levels of NF-1, Her-2/neu, c-Raf-1, and Wnt-1 genes were evaluated post-treatment using flow cytometry and RT-PCR, respectively. The obtained NPs were spherical with a suitable dispersity without noticeable aggregation. The size of the NPs, polydispersity, and zeta were 74 ± 13 nm, 0.080 and 45 mV, respectively. The results of the encapsulation efficiency of the nano-compound showed highly colloidal stability and proper drug maintenance. The results indicated that FA-DEX-5-FU-SPION demonstrated a sustained release profile of 5-FU in both phosphate and citrate buffer solutions separately, with higher cytotoxicity against SNU-423 cells than against other cells types. These findings suggest that FA-DEX-SPION NPs exert synergistic effects for targeting intracellular delivery of 5-FU, apoptosis induction, and gene expression stimulation. CONCLUSIONS: The findings proved that FA-DEX-5-FU-SPION presented remarkable antitumor properties; no adverse subsequences were revealed against normal cells.

Humans , Carcinoma, Hepatocellular/drug therapy , Fluorouracil/administration & dosage , Liver Neoplasms/drug therapy , Polymers , Gene Expression/drug effects , Drug Delivery Systems , Apoptosis/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Delayed-Action Preparations , Nanoparticles/administration & dosage , Magnetite Nanoparticles , Flow Cytometry
Article in Chinese | WPRIM | ID: wpr-921529


Objective To establish a human colon cancer cell line HCT-116/5-FU resistant to 5-fluorouracil(5-FU)and explore the relationship between runt-related transcription factor 3(RUNX3)and drug resistance of colorectal cancer.Methods The human colon cancer cell line HCT-116/5-FU with resistance to 5-FU was established by low concentration gradient increment combined with high-dose intermittent shock.CCK-8 method was used to determine the half maximal inhibitory concentration(IC

Cell Line, Tumor , Colonic Neoplasms/genetics , Core Binding Factor Alpha 3 Subunit , Drug Resistance, Neoplasm , Fluorouracil/pharmacology , Humans , Transcription Factor 3
Chinese Medical Journal ; (24): 2475-2482, 2021.
Article in English | WPRIM | ID: wpr-921116


BACKGROUND@#There is growing evidence that 5-fluorouracil (5-FU) combined with therapeutic trauma can effectively induce skin repigmentation in vitiligo patients who are unresponsive to conventional treatments. Previous studies have mainly focused on identifying the antimitotic activity of 5-FU for the treatment of skin cancer, but few studies have investigated its extra-genotoxic actions favoring melanocyte recruitment.@*METHODS@#We utilized the full thickness excisional skin wound model in Dct-LacZ transgenic mice to dynamically assess the migration of melanocytes in the margins of wounds treated with or without 5-FU. The in-situ expression of CXCL12 was examined in the wound beds using immunofluorescence staining. Quantitative real-time polymerase chain reaction and Western blotting analyses were performed to detect the expression levels of CXCL12 mRNA and protein in primary mouse dermal fibroblasts treated with or without 5-FU. Transwell assays and fluorescein isothiocyanate (FITC)-phalloidin staining were used to observe cell migration and filamentous actin (F-actin) changes of melan-a murine melanocytes.@*RESULTS@#Whole mount and cryosection X-gal staining showed that the cell numbers of LacZ-positive melanocytes were much higher in the margins of dorsal and tail skin wounds treated with 5-FU compared with the controls. Meanwhile, CXCL12 immunostaining was significantly increased in the dermal compartment of wounds treated with 5-FU (control vs. 5-FU, 22.47 ± 8.85 vs. 44.69 ± 5.97, P < 0.05). Moreover, 5-FU significantly upregulated the expression levels of CXCL12 mRNA (control vs. 5-FU, 1.00 ± 0.08 vs. 1.54 ± 0.06, P < 0.05) and protein (control vs. 5-FU, 1.00 ± 0.06 vs. 2.93 ± 0.10, P < 0.05) in cultured fibroblasts. Inhibition of the CXCL12/CXCR4 axis suppressed melanocyte migration in vitro using a CXCL12 small interfering RNA (siRNA) or a CXCR4 antagonist (AMD3100).@*CONCLUSION@#5-FU possesses a pro-pigmentary activity through activation of the CXCL12/CXCR4 axis to drive the chemotactic migration of melanocytes.

Animals , Cell Movement , Cell Proliferation , Chemokine CXCL12/genetics , Fibroblasts , Fluorouracil/therapeutic use , Humans , Mice , RNA, Messenger , Receptors, CXCR4
Article in Chinese | WPRIM | ID: wpr-888620


Colorectal cancer is the second most common malignant tumor in China. The FOLFOXIRI regimen, which combines 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan, is a high-intensity and highly effective chemotherapy regimen. However, the original regimen is poorly tolerated in Chinese patients. In order to promote the standardized and rational application of FOLFOXIRI regimen by clinicians in China, "

Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/therapeutic use , China , Colorectal Neoplasms/drug therapy , Consensus , Fluorouracil/therapeutic use , Humans , Irinotecan/therapeutic use , Leucovorin/therapeutic use , Organoplatinum Compounds/therapeutic use , Oxaliplatin , Treatment Outcome
Article in Chinese | WPRIM | ID: wpr-878893


This study aims to investigate the potential mechanism of curcumin in mediating interleukin-6(IL-6)/signal transducer and activator of transcription 3(STAT3) signaling pathway to repair intestinal mucosal injury induced by 5-fluorouracil(5-FU) chemotherapy for colon cancer. SD rats were intraperitoneally injected with 60 mg·kg~(-1)·d~(-1) 5-FU for 4 days to establish a model of intestinal mucosal injury. Then the rats were randomly divided into model group(equal volume of normal saline), curcumin low, medium and high dose groups(50, 100, 200 mg·kg~(-1)), and normal SD rats were used as control group(equal volume of normal saline). Each group received gavage administration for 4 consecutive days, and the changes of body weight and feces were recorded every day. After administration, blood was collected from the heart, and jejunum tissues were collected. The levels of serum interleukin-1β(IL-1β) and tumor necrosis factor-α(TNF-α) were detected by ELISA, and at the same time, the concentration of Evans blue(EB) in jejunum was measured. Hematoxylin-eosin(HE) staining was used to observe the pathological state of jejunum, and the length of jejunum villi and the depth of crypt were measured. The positive expression levels of claudin, occludin and ZO-1 were detected by immunohistochemistry. Western blot was used to detect the protein expression of IL-6, p-STAT3, E-cadherin, vimentin and N-cadherin in jejunum tissues. The results showed that, curcumin significantly increased body weight and fecal weight(P<0.05 or P<0.01), decreased fecal score, EB concentration, IL-1β and TNF-α levels(P<0.05 or P<0.01) in rats. In addition, curcumin maintained the integrity of mucosal surface and villi structure of jejunum to a large extent, and reduced pathological changes in a dose-dependent manner. Meanwhile, curcumin could increase the positive expression of occludin, claudin and ZO-1(P<0.05 or P<0.01), repair intestinal barrier function, downregulate the protein expression of IL-6, p-STAT3, vimentin and N-cadherin in jejunum tissues(P<0.05 or P<0.01), and upregulate the protein expression of E-cadherin(P<0.05). Therefore, curcumin could repair the intestinal mucosal injury induced by 5-FU chemotherapy for colon cancer, and the mechanism may be related to the inhibition of IL-6/STAT3 signal and the inhibition of epithelial-mesenchymal transition(EMT) process.

Animals , Colonic Neoplasms/drug therapy , Curcumin , Fluorouracil/toxicity , Interleukin-6/genetics , Intestinal Mucosa/metabolism , Rats , Rats, Sprague-Dawley , STAT3 Transcription Factor/metabolism , Signal Transduction
Article in English | WPRIM | ID: wpr-880619


OBJECTIVES@#Neoadjuvant chemotherapy combined with radical surgery has become the treatment model for locally advanced rectal cancer. The purpose of this study was to evaluate the safety and efficacy of postoperative mFOLFOX6 regimen chemotherapy for locally resectable advanced rectal cancer.@*METHODS@#This was a prospective study. A total of 82 patients with locally advanced rectal cancer admitted to Affiliated Nanhua Hospital, University of South China from February 2015 to December 2017 were selected as the subjects. The patients received 4 courses of mFOLFOX6 chemotherapy and underwent surgery within 4-6 weeks after chemotherapy. The incidences of chemotherapy-related adverse reactions, postoperative complications, and clinical pathological reactions were analyzed.@*RESULTS@#In the period from mFOLFOX6 chemotherapy to preoperative, 82 patients with locally advanced rectal cancer was reported chemotherapy-related adverse reactions, including Grade 4 neutropenia (2.4%), catheter related infection (2.4%), and anorexia (2.4%), Grade 3 nausea (2.4%) and anorexia (2.4%), Grade 2 neutropenia (14.6%) and peripheral neuropathy (7.3%). Finally, 76 patients with locally advanced rectal cancer completed surgery, including 56 (73.7%) with anterior rectum resection, 16 (21.1%) with abdominal perineal resection, and 72 (94.7%) with pelvic nerve preservation. A total of 22 (28.9%) patients had surgical complications, including 8 (10.5%) with complications of Grade 3 or above. The complications with high incidence were intestinal obstruction, anastomotic leakage, and sepsis. Among the 76 patients who completed chemotherapy and surgery, T stage was decreased in 28 (36.8%) and N stage was decreased in 44 (57.9%); forty-two (55.3%) were in pathological Stage I, 20 (26.3%) in Stage IIA, 12 (15.8%) in Stage IIB, and 2 (2.6%) in Stage IIIA. Ten patients were suspected of tumor invasion of surrounding organs before chemotherapy, of which 4 patients did not need to extend the resection of surrounding organs after chemotherapy and achieved R0 resection of tumor; 2 in T@*CONCLUSIONS@#Preoperative mFOLFOX6 regimen chemotherapy for locally resectable advanced rectal cancer is a safe and feasible treatment strategy, and it is worthy of clinical application.

Antineoplastic Combined Chemotherapy Protocols/adverse effects , China , Fluorouracil/adverse effects , Humans , Neoadjuvant Therapy , Neoplasm Staging , Prospective Studies , Rectal Neoplasms/surgery , Treatment Outcome
Repert.Med.Cir ; 30(3): 248-255, 2021. ilus., tab.
Article in English, Spanish | LILACS, COLNAL | ID: biblio-1363530


Objetivo: evaluar la eficacia de la combinación de radioterapia y 5-fluorouracilo-cisplatino en el tratamiento del cáncer de cuello uterino de alto riesgo. Materiales y métodos: estudio retrospectivo en el que se revisaron los datos de pacientes tratadas en el periodo enero 2009 a diciembre 2019 en el Hospital Central "Dr. Urquinaona", Maracaibo, Venezuela. Se revisaron los registros clínicos de todas las pacientes sometidas a histerectomía radical y linfadenectomía pélvica bilateral que recibieron quimio-radioterapia concurrente adyuvante con 5-fluorouracilo-cisplatino (grupo de tratamiento) y se compararon con quienes no fueron manejadas con este régimen, las que no recibieron ningún tratamiento adyuvante o solo fueron tratadas con radioterapia (grupo control). Se evaluaron las características generales, efectos adversos del tratamiento, recurrencias de la enfermedad y supervivencia. Resultados: para el análisis final quedaron 164 pacientes, de las cuales 115 (70,1%) fueron del grupo de tratamiento y 49 (29,9%) del control. No se encontraron diferencias estadísticamente significativas en las características clínicas entre ambos grupos (p = ns); sí las hubo en la frecuencia de recurrencias a distancia (p = 0,0056). La supervivencia libre de progresión y la global de ambos grupos no mostraron diferencias significativas (p = 0,2678 y p = 0,3452). Conclusión: no existen beneficios evidentes del uso de 5-fluorouracilo-cisplatino desde el punto de vista de progresión o supervivencia general, en pacientes con carcinoma cuello uterino de alto riesgo.

Objective: to evaluate the efficacy of radiotherapy combined with 5-fluorouracil-cisplatin in the treatment of high-risk uterine cervical cancer. Materials and methods: Retrospective study, in which the data of patients treated between January 2009 and December 2019 at Hospital Central "Dr. Urquinaona", Maracaibo, Venezuela, was analyzed. The clinical records of all patients who underwent radical hysterectomy and bilateral pelvic lymphadenectomy and received adjuvant concurrent chemoradiotherapy with 5-fluorouracil-cisplatin (treatment group) compared with those patients not managed with this regimen, those who did not receive any adjuvant treatment or received only radiotherapy (control group), were reviewed. The general characteristics, treatment adverse effects, disease recurrences and survival rate were evaluated. Results: 164 patients remained for the final analysis, of which 115 (70.1%) were in the treatment group and 49 (29.9%) in the control group. No statistically significant differences were found in the clinical characteristics of patients between the two groups (p = ns); while differences in the distant recurrence rate (p = 0.0056) were found. Progression-free survival and overall survival in both groups did not show significant differences (p = 0.2678 and p = 0.3452). Conclusion: there is no evident benefit of the use of 5-fluorouracil-cisplatin in terms of progression or overall survival in patients with high-risk cervical carcinoma.

Humans , Female , Middle Aged , Radiotherapy , Uterine Cervical Neoplasms , Fluorouracil , Survival , Therapeutics , Cisplatin
Braz. J. Pharm. Sci. (Online) ; 57: e18954, 2021. tab, graf
Article in English | LILACS | ID: biblio-1345456


The ethanolic extract of resinous sediment (EERS) of Etlingera elatior young inflorescence was examined for its anticancer effect and potential antioxidant activity. The anticancer effect of the EERS was evaluated on four human cancer cell lines, HCT 116, HT-29, Hela, and MCF-7, using the MTT assay. GC-MS analysis showed that the main components found in the EERS were nonyl cyclopropane (4.44%), 1-tetradecane (3.66%), cyclotetradecane (2.41%), cyclododecane (1.92%), and 1-decene (1.72%). The antioxidant activity was determined through different methods. High amounts of TPC and TFC in the EERS were found. Moderate antioxidant capacity of the EERS was detected by DPPH and ABTS assays, with EC50 values of 44.19 and 56.61 µg/mL and a high FRAP value of 281.79 nmol Fe+2 equivalent/mg extract. In the MTT assay, the EERS showed potent anticancer activity, with IC50 values of 19.82, 37.001, 50.49, and 53.29 µg/mL against HT-29, HCT 116, Hela, and MCF-7 tumour cell lines, respectively. Moreover, the results were comparable to or less potent than the standard reference drug, 5-fluorouracil. The results showed that the EERS of Etlingera elatior inflorescence contained a high amount of polyphenols and flavonoids, which may to the selective antiproliferative effects towards colon cancer in vitro

Zingiberaceae/classification , Inflorescence/anatomy & histology , Fluorouracil/pharmacology , Neoplasms , Antioxidants/analysis , In Vitro Techniques/methods , Pharmaceutical Preparations , Anticarcinogenic Agents/adverse effects , Colonic Neoplasms/pathology
Notas enferm. (Córdoba) ; 20(36): 70-77, nov.2020.
Article in Spanish | LILACS, BDENF, BINACIS, UNISALUD | ID: biblio-1140731


Introducción. Este espacio es acerca del empleo de bombas elastoméricas en la administración de citostáticos de infusión continua con pacientes oncológicos que reciben tratamiento endovenoso, de infusión continua en el domicilio, mejorando así la calidad de vida del paciente, (esta experiencia es sólo en relación a aplicación de 5 fluorouracilo).Material y método: Al inicio, la primera dosis de quimioterapia, se realiza en el internado común para observar la tolerancia a la medicación, y en la segunda o tercera aplicación se realiza la misma en el hospital de día la primera parte del esquema, y luego se realiza la conexión de la bomba elastomérica que infundirá durante 46hs con el 5 fluorouracilo. El paciente asistirá al hospital oncológico para realizar la desconexión. Nuestro rol enfermero de contención y capacitación es necesario y así poder asegurar el buen manejo del dispositivo y brindar seguridad a los pacientes, para que logren un cuidado autónomo, seguro y eficaz. Para tal fin se les provee un instructivo. Poseer catéter implantable es requisito obligatorio para esta modalidad. Beneficios encontrados: es portátil y ergonómico, Mejora la movilidad y autocuidado, tasa de infusión exacta. Características de seguridad, que incluyan la protección del reservorio frente a posibles daños; Descomprimimos las internaciones, reducimos la espera de camas para internación de pacientes. Reducimos el uso de bombas comunes eléctricas del internado quedando a disponibilidad para otros pacientes hospitalizados. Dificultades halladas: Desconocimiento del paciente sobre el insumo (bomba). Inseguridad del paciente al encontrarse en el hogar por primera vez. Trámites burocráticos para autorización de la bomba. Conclusión: esta implementación innovadora requiere aún más aprendizaje, contamos con el apoyo del Departamento de Enfermería y la jefatura del servicio del Hospital de Día Oncológico, para el uso de las bombas. Para esta experiencia se utilizaron 10 bombas elastoméricas. Experiencia práctica, positiva para el paciente, además él mismo se compromete con su autocuidado y tratamiento, se logra evitar las exposiciones nosocomiales minimizando así los riesgos de contagios. Reducimos el uso de bombas comunes eléctricas del internado quedando a disposición para otros pacientes que lo requieran. Descomprimimos el internado común permitiendo así contar con más camas y mayor fluidez para satisfacer la demanda de internación de pacientes con otras patologías[AU]

Introduction. This space is about the use of elastomeric pumps in the administration of cytostatics of continuous infusion with cancer patients who receive intravenous treatment, of continuous infusion of qmt at home, thus improving the quality of life of the patient, (this experience is only in relation to to application of 5 fluorouracil). Material and method: At the beginning, the first dose of chemotherapy is carried out in the common boarding school to observe the tolerance to the medication, and in the second or third application it is carried out in the day hospital the first part of the scheme, and then the elastomeric pump is connected, which will infuse for 46 hours with 5 fluorouracil. The patient will attend the cancer hospital at hour 46 to perform the disconnection. Our nursing role of containment and training is necessary in order to ensure the proper handling of the device and provide safety to patients, so that they achieve autonomous, safe and effective care. For this purpose, an instruction manual is provided. Having an implantable catheter is a mandatory requirement for this modality; Benefits found: It is portable and ergonomic, Improves mobility and self-care, exact infusion rate. Safety features, including protection of the reservoir against possible damage; We decompressed hospitalizations, we reduced the wait for beds for patient admission. We reduced the use of common electric pumps in the internship, making them available for other hospitalized patients. Difficulties encountered: Lack of knowledge of the patient about the input (pump). Patient insecurity when being at home for the first time. Bureaucratic procedures for authorization of the pump. Conclusion. This innovative implementation requires even more learning, we have the support of the Nursing Department and the head of the Oncology Day Hospital service, for the use of the pumps. For this experiment 10 elastomeric pumps were used. Practical experience, positive for the patient, he also commits himself to self-care and treatment, it is possible to avoid nosocomial exposures, thus minimizing the risks of contagion. We reduce the use of common electric pumps in the internship by being available for other patients who require it. We decompress the common boarding school, thus allowing us to have more beds and greater fluidity to satisfy the demand for hospitalization of patients with other pathologies[AU]

Introdução. Este espaço trata da utilização de bombas elastoméricas na administração de citostáticos de infusão contínua em pacientes oncológicos que recebem tratamento intravenoso, de infusão contínua de qmtem casa, melhorando assim a qualidade de vida do paciente, (esta experiência é apenas emrelação a aplicação de 5 fluorouracil). Material e método: No início, a primeira dose de quimioterapia é realizada no colégio interno comum para observar a tolerânciaao medicamento, e na segunda ou terceira aplicação é realizada em hospital dia a primeira parte do esquema, e em seguida, a bomba elastomérica é conectada, que fará a infusão de 5 fluorouracil por 46 horas. O paciente comparecerá ao hospital oncológico na hora 46 para realizar o desligamento. Nosso papel de enfermagem de contenção e treinamento é necessário a fim de garantir o correto manuseio do dispositivo e dar segurançaaos pacientes, para que alcancem um cuidado autônomo, seguro e eficaz. Para tal, é fornecido um manual de instruções. Ter Um catéter implantável é requisito obrigatório para esta modalidade; Benefícios encontrados: É portátil e ergonômico, melhora a mobilidade e o autocuidado, taxa de infusão exata. Recursos de segurança, incluindo proteção do reservatório contra possíveis danos; Descomprimimos internações, reduzimos a espera por leitos para admissão de pacientes .Reduzimos o uso de bombas elétricas comuns no internato, disponibilizando-as para outros pacientes internados. Dificuldades encontradas: Falta de conhecimento do paciente sobre o insumo (bomba). Insegurança do paciente ao estar em casa pela primeira vez. Procedimentos burocráticos para autorização da bomba. Conclusão. Esta implementação inovadora exige ainda mais aprendizagem, contamos com o apoio do Departamento de Enfermagem e do chefe do serviço de Oncologia-Dia Hospital, para utilização das bombas. Para esta experiencia foram utilizadas 10 bombas elastoméricas. Experiência prática, positiva para o paciente, ele também se compromete com o autocuidado e o tratamento, sendo possível evitar exposições nosocomiais, minimizando assim os riscos de contágio. Reduzimos o uso de bombas elétricas comuns no estágio, disponibilizando para outros pacientes que necessitem. Descomprimimos o internato comum, permitindo assim ter Mais leitos e maior fluidez para atender a demanda de internação de pacientes como utras patologias[AU]

Humans , Self Care , Infusion Pumps , Cytostatic Agents/administration & dosage , Ambulatory Care , Fluorouracil/administration & dosage
Braz. dent. j ; 31(3): 310-318, May-June 2020. graf
Article in English | LILACS, BBO | ID: biblio-1132308


Abstract Oral mucositis is a common inflammatory complication among patients with cancer. This study evaluated the histopathological, stereological, and antioxidant markers of 2% eucalyptus extract in induced oral mucositis in male golden hamsters. In this animal study, oral mucositis was induced in 30 male golden hamsters by 5-FU (60 mg/kg) on days 0, 5, and 10 of the study. The cheek pouch was scratched with a sterile needle once daily on days 3 and 4. On days 14-17, 2% eucalyptus hydroalcoholic extract gel and Calendula officinalis extract gel groups were treated and then compared with a non-treated control group. The histopathological and stereological scores and the pouch content of malondialdehyde, as well as the activities of glutathione and myeloperoxidase in the pouch tissue, were evaluated. Histopathologic scores of oral mucositis were lower in the eucalyptus gel group than those of the calendula and control groups (p<0.05). Also, a lower malondialdehyde level and higher myeloperoxidase and glutathione activities were detected in the eucalyptus group in comparison to the calendula and control groups (p<0.001). The thickness of the mucosa and submucosa increased in the eucalyptus group. The numerical density of the fibroblast and the volume density of the collagen significantly increased in the eucalyptus group. In conclusion, the use of eucalyptus hydroalcoholic extract may be associated with reduced intensity of oral mucositis, diminished concentration of malondialdehyde, increased activity of myeloperoxidase and glutathione, increased volume of mucosa and submucosa, increased fibroblast and collagen in the induced oral mucositis in golden hamsters undergoing 5-FU consumption.

Resumo A mucosite oral é uma complicação inflamatória comum em pacientes com câncer. Este estudo avaliou os marcadores histopatológicos, estereológicos e antioxidantes de Eucalyptus 2% na mucosite oral induzida em hamsters dourados machos. Neste estudo em animais, a mucosite oral foi induzida em 30 hamsters golden masculinos por 5-FU (60 mg / kg) nos dias 0, 5 e 10 do estudo. A bolsa da bochecha foi arranhada com uma agulha estéril uma vez ao dia nos dias 3 e 4. Nos dias 14 a 17, os grupos de gel de eucalipto a 2% e curativos à base de gel foram tratados e comparados com um grupo controle. Foram avaliados os escores histopatológicos e estereológicos e o conteúdo de malondialdeído na bolsa, bem como as atividades de glutationa e mieloperoxidase no tecido da bolsa. Os escores histopatológicos de mucosite foram menores no grupo de gel de eucalipto a 2% do que os do gel e do grupo controle (p <0,05). Além disso, um nível mais baixo de malondialdeído e maiores atividades de mieloperoxidase e glutationa foram detectadas no grupo tratado com eucalipto em comparação aos grupos à base de gel e controle (p <0,001). A espessura da mucosa e submucosa aumentou no grupo Eucalyptus. A densidade numérica do fibroblasto e a densidade do volume do colágeno aumentaram significativamente nos grupos tratados com eucalipto. Em conclusão, o uso do extrato hidroalcoólico de Eucalyptus pode estar associado a menor intensidade de mucosite oral, diminuição da concentração de malondialdeído, aumento da atividade de mieloperoxidase e glutationa, aumento do volume de mucosa e submucosa, aumento de fibroblastos e colágeno na mucosite oral induzida em hamsters dourados em consumo de 5 UF.

Animals , Male , Stomatitis , Mucositis , Eucalyptus , Plant Extracts , Cricetinae , Mesocricetus , Fluorouracil , Mouth Mucosa
Article in Chinese | WPRIM | ID: wpr-878839


This paper discussed the synergistic anti-tumor effect of Shuangdan Capsules combined with 5-fluorouracil(5-FU) on human liver cancer cell line Huh-7 and tumor bearing mice. The effects of Shuangdan Capsules combined with 5-FU on the activity and vascular endothelial growth factor(VEGF) receptor protein expression of Huh-7 cells were investigated, and the effects of drug combination on tube formation of HUVEC cell were also verified. In addition, the mice model of Huh-7 was established to observe the anti-tumor effect of drug combination and the distribution of tumor blood flow in tumor bearing mice by using molecular imaging. HPLC analysis showed that Shuangdan Capsules mainly consisted of danshensusodium, protocatechuic aldehyde, paeoniflorin, rosmarinic acid, alkannic acid, salvianolic acid B, and paeonol. In MTT experiment, the inhibition rate of Shuangdan Capsules(20 mg·L~(-1)) and 5-FU(1 μmol·L~(-1)) on Huh-7 cells was 60%, and the CI value was 0.59, suggesting that these two drugs had synergistic anti-hepatoma cells effect. The expression of VEGF receptor in Huh-7 cells was inhibited by the combination of these two drugs. In addition, the process of HUVEC was slow, and the number, length and area of the lumen branches decreased significantly. In vivo, Shuangdan Capsules combined with 5-FU inhibited the growth and prolongation of survival of Huh-7 cells in subcutaneous transplanted tumor nude mice; serum expression of CD31 and VEGF in nude mice were decreased, while caspase-3 was increased. Meanwhile, the drug combination significantly inhibited the expressions of MMP2 and VEGF in tumor tissues. Ultrasound showed that Shuangdan Capsules combined with 5-FU also inhibited tumor angiogenesis and reduced blood flow of tumor tissue. The results showed that Shuangdan Capsules combined with 5-FU may inhibit tumor angiogenesis by inhibiting VEGF and MMP2 expressions, thereby blocking tumor growth.

Animals , Capsules , Carcinoma, Hepatocellular , Cell Line, Tumor , Cell Proliferation , Drugs, Chinese Herbal , Fluorouracil , Heterografts , Liver Neoplasms , Mice , Mice, Nude , Vascular Endothelial Growth Factor A , Xenograft Model Antitumor Assays
Rev. latinoam. enferm. (Online) ; 28: e3363, 2020. tab, graf
Article in English | LILACS, BDENF | ID: biblio-1139216


Objective: to evaluate the effect of oral cryotherapy compared to physiological serum on the development of oral mucositis in outpatient cancer patients using the 5-fluorouracil antineoplastic agent. Method: this is a controlled, randomized, double-blind, and multi-center clinical trial, conducted with 60 patients undergoing chemotherapy. The experimental group (n=30) used oral cryotherapy during the infusion of the 5-FU antineoplastic agent, while the control group (n=30) performed mouthwash with physiological serum at their homes. The oral cavity of the participants was assessed at three times: before randomization, and on the 7th and 14th days after using 5-FU. For data analysis, descriptive analyses and the ANOVA, paired t, and McNemar tests were used. Results: there was no statistically significant difference between the experimental and control groups in the assessments regarding the grade of mucositis. However, cryotherapy presented the chance to reduce the presence of intragroup mucositis, between the first and second assessments (p=0.000126). Conclusion: cryotherapy did not obtain statistical significance in relation to oral hygiene with serum, but it proved to be effective intragroup. Record number: RBR-4k7zh3

Objetivo: avaliar o efeito da crioterapia oral em comparação ao soro fisiológico no desenvolvimento de mucosite oral em pacientes oncológicos ambulatoriais em uso de antineoplásico 5-fluorouracil. Método: trata-se de um ensaio clínico controlado, randomizado, duplo-cego, multicêntrico, realizado com 60 pacientes em tratamento quimioterápico. O grupo experimental (n=30) fez uso de crioterapia oral durante a infusão do antineoplásico 5-FU, ao passo que o grupo controle (n=30) realizou bochechos com soro fisiológico em domicílio. A cavidade oral dos participantes foi avaliada em três momentos: antes da randomização, no 7° dia e no 14° dia após o uso do 5-FU. Para a análise dos dados, utilizaram-se análises descritivas e os testes ANOVA, t pareado e McNemar. Resultados: não houve diferença estatística significante entre os grupos experimental e controle nas avaliações quanto ao grau de mucosite. No entanto, a crioterapia teve a chance de reduzir a presença de mucosite intragrupo, entre a primeira e segunda avaliação (p=0,000126). Conclusão: a crioterapia não obteve significância estatística em relação à higiene oral com soro, porém se mostrou efetiva intragrupo. Número de registro: RBR-4k7zh3

Objetivo: evaluar el efecto de la crioterapia oral, comparándola con el suero fisiológico, sobre el desarrollo de mucositis oral en pacientes ambulatorios con cáncer en tratamiento con el antineoplásico 5-fluorouracilo. Método: se trata de un ensayo clínico controlado, aleatorizado, a doble ciego y multicéntrico, realizado con 60 pacientes en tratamiento de quimioterapia. El grupo experimental (n=30) utilizó crioterapia oral durante la administración del agente antineoplásico 5-FU, mientras que el grupo control (n=30) realizó enjuagues con suero fisiológico en su domicilio. La cavidad oral de los participantes se evaluó en tres momentos: antes de la aleatorización, y al 7º y 14º día después de la administración de 5-FU. Para el análisis de los datos, se utilizaron análisis descriptivos y las pruebas ANOVA, t pareada y McNemar. Resultados: en lo que respecta al grado de mucositis, no se registraron diferencias estadísticamente significativas entre el grupo experimental y el de control en las evaluaciones. Sin embargo, la crioterapia exhibió la posibilidad de reducir la presencia de mucositis intragrupo entre la primera y la segunda evaluación (p=0,000126). Conclusión: la crioterapia no alcanzó significancia estadística en comparación con la higiene oral con suero. Sin embargo, demostró ser efectiva intragrupo. Número de registro: RBR-4k7zh3

Humans , Oral Hygiene , Stomatitis , Pharmaceutical Preparations , Hygiene , Control Groups , Cryotherapy , Drug Therapy , Disease Prevention , Mucositis , Fluorouracil , Antineoplastic Agents
J. oral res. (Impresa) ; 8(5): 363-369, oct. 31, 2019. tab, graf
Article in English | LILACS | ID: biblio-1248086


Objective: Chemotherapy treatment against cancer produce systemic toxicities, among which are those related to important structures of the stomatognathic system and its functional activity. 5 Fluorouracil (5-FU) and cyclophosphamide (Cf) are drugs widely used in solid tumors and in bone marrow transplantation, respectively. The objective of this work was to evaluate the toxicity of these drugs regarding functional activity of the submandibular glands, by measuring the percentage of glycogen consumption in two experimental models. Material and Methods: 84 male Wistar rats aged three months were used, housed in individual cages, with controlled temperature and lighting and ad libitum diet. They were divided into four experimental groups: 1) Control (C); 2) Treated with 5-FU+leucovorin (LV) at 20 and 10mg/Kg of body weight respectively for five consecutive days; 3) treated with Cf i.p. at 50mg/Kg of body weight for two consecutive days; and 4) rats with paired feeding (PF): for five and two days respectively, the amount administered resulted from the average of the ingested food of groups 2 and 3. Both submandibular glands were excised. The submandibular glycogen concentration was analyzed at initial time (t0) and after 60 minutes of mechanical stimulation (t60). Results: the average variation changed significantly between time 0 and 60 in the groups C and PF. (p-value=0.0001), the 5-FU + LV treatment group had an average concentration higher at t0 than groups C and PF, without significant consumption at T60. While group Cf showed a lower average concentration at time 0 with respect to groups C and PF, without significant consumption at T60. Conclusion: 5-FU+LV and Cf affect the metabolism of carbohydrates, decreasing the use of glycogen as a metabolic substrate. In the present experimental model, the toxicity of these drugs affected the functional activity of the submandibular gland.

Objetivo: el tratamiento de quimioterapia contra el cáncer produce toxicidades sistémicas, entre las que se encuentran las relacionadas con estructuras importantes del sistema estomatognático y su actividad funcional. El 5-fluorouracilo (5-FU) y la ciclofosfamida (Cf ) son fármacos ampliamente utilizados en tumores sólidos y en trasplantes de médula ósea, respectivamente. El objetivo de este trabajo fue evaluar la toxicidad de estos fármacos con respecto a la actividad funcional de las glándulas submandibulares, midiendo el porcentaje de consumo de glucógeno en dos modelos experimentales. Material y Métodos: se utilizaron 84 ratas Wistar machos de tres meses de edad, alojadas en jaulas individuales, con temperatura e iluminación controladas y dieta ad libitum. Se dividieron en cuatro grupos experimentales: 1) Control (C); 2) Tratados con 5-FU+leucovorina (LV) a 20 y 10mg/Kg de peso corporal, respectivamente, durante cinco días consecutivos; 3) tratados con Cf i.p. a 50mg/Kg de peso corporal durante dos días consecutivos; y 4) ratas con alimentación por parejas (PF): durante cinco y dos días respectivamente, la cantidad administrada resultó del promedio de los alimentos ingeridos de los grupos 2 y 3. Ambas glándulas submandibulares fueron extirpadas. La concentración de glucógeno submandibular se analizó en el momento inicial (t0) y después de 60 minutos de estimulación mecánica (t60). Resultados: la variación promedio cambió significativamente entre el tiempo 0 y 60 en los grupos C y PF. (p=0,0001), el grupo de tratamiento 5-FU+LV tuvo una concentración promedio más alta en t0 que los grupos C y PF, sin un consumo significativo en T60. Mientras que el grupo Cf mostró una concentración promedio más baja en el tiempo 0 con respecto a los grupos C y PF, sin un consumo significativo en T60. Conclusión: 5-FU + LV y Cf afectan el metabolismo de los carbohidratos, disminuyendo el uso de glucógeno como sustrato metabólico. En el presente modelo experimental, la toxicidad de estos medicamentos afectó la actividad funcional de la glándula submandibular.

Animals , Rats , Submandibular Gland/physiology , Cyclophosphamide/adverse effects , Fluorouracil/adverse effects , Glycogen/metabolism , Rats, Wistar , Cyclophosphamide/therapeutic use , Fluorouracil/therapeutic use , Antineoplastic Agents
Säo Paulo med. j ; 137(5): 438-445, Sept.-Oct. 2019. tab, graf
Article in English | LILACS | ID: biblio-1059106


ABSTRACT BACKGROUND: Management of rectal cancer has become more complex with multimodality therapy (neoadjuvant chemoradiotherapy and surgery) and this has led to the need to organize multidisciplinary teams. The aim of this study was to report on the planning, implementation and evaluation of an integrated care pathway for neoadjuvant treatment of middle and lower rectal cancer. DESIGN AND SETTING: This was a cross-sectional post-implementation study that was carried out at a public university cancer center. METHODS: The Framework for Program Evaluation in Public Health of the Centers for Disease Control and Prevention (CDC) was used to identify resources and activities; link results from activities and outcomes with expected goals; and originate indicators and outcome measurements. RESULTS: The logic model identified four activities: stakeholders' engagement, clinical pathway development, information technology improvements and training programs; and three categories of outcomes: access to care, effectiveness and organizational outcomes. The measurements involved 218 patients, among whom 66.3% had their first consultation within 15 days after admission; 75.2% underwent surgery < 14 weeks after the end of neoadjuvant treatment and 72.7% completed the treatment in < 189 days. There was 100% adherence to the protocol for the regimen of 5-fluorouracil and leucovorin. CONCLUSIONS: The logic model was useful for evaluating the implementation of the integrated care pathways and for identifying measurements to be made in future outcome studies.

Humans , Rectal Neoplasms/therapy , Program Evaluation/methods , Critical Pathways/standards , Neoadjuvant Therapy/standards , Rectal Neoplasms/surgery , Rectal Neoplasms/drug therapy , Brazil , Program Evaluation/standards , Antineoplastic Combined Chemotherapy Protocols , Logistic Models , Leucovorin/therapeutic use , Cross-Sectional Studies , Combined Modality Therapy , Fluorouracil/therapeutic use
Arq. bras. oftalmol ; 82(5): 372-376, Sept.-Oct. 2019. tab, graf
Article in English | LILACS | ID: biblio-1019436


ABSTRACT Purpose: We evaluated the role of the conjunctival flap rotation technique using 5-fluorouracil and adjuvant therapy with topical cyclosporine A at 0.05% during short pre- and postoperative periods for the prevention of primary pterygium recurrence. Methods: In this prospective study, 76 patients with primary pterygium (76 eyes) were categorized into two groups: the control group with 31 patients who did not receive cyclosporine treatment, and the cyclosporine group with 45 patients who received topical cyclosporine A (0.05%) twice a day, for 10 days before and 10 days after the pterygium excision operations. Patients were examined for disease recurrence, side effects, and complications at 10 and 21 days, and at 2 and 6 months after the operation. Data on demography, systemic diseases, and ophthalmologic histories were obtained from all patients, and these data were analyzed using descriptive statistics involving the absolute and relative percentages of frequency distribution. Goodman test was used for contrasts among multinomial populations to study the association between cyclosporine A and recurrence. Results: Most patients were between 30 and 60 years of age, and 67.1% were women. We confirmed a higher recurrence in patients with occupational sunlight exposure. The cyclosporine A used topically 10 days before and 10 days after the pterygium removal did not significantly reduce the recurrence of the pterygium. Conclusion: Topical 0.05% cyclosporine A when used for 10 days before and 10 days after the pterygium removal does not prevent or reduce the recurrence of primary pterygium.

RESUMO Objetivo: Avaliamos os resultados da técnica de rotação de retalho conjuntival com uso de 5-fluorouracil e terapia adjuvante com ciclosporina A tópica a 0,05%, usada no pré e pós-operatório por curto período, quanto à prevenção da recidiva do pterígio primário Métodos: Estudo prospectivo, com 76 pacientes portadores de pterígio primário (76 olhos), divididos em dois grupos: controle com 31 pacientes que não receberam tratamento com ciclosporina e grupo ciclosporina com 45 pacientes que receberam ciclosporina tópica A (0,05%) duas vezes ao dia, por 10 dias antes e 10 dias após a cirurgia de excisão do pterígio. Os pacientes foram avaliados quanto à recorrência, efeitos colaterais e complicações com 10, 21 dias, 2 e 6 meses de pós-operatório. Dados demográficos, doenças sistêmicas e histórico oftalmológico foram coletados de todos os pacientes e esses dados foram analisados por meio de estatística descritiva envolvendo o percentual absoluto e relativo de distribuição de frequência. O teste de Goodman para contrastes entre populações multinomiais foi utilizado para o estudo da associação entre a ciclosporina A e a recorrência Resultados: A maioria dos pacientes tinha entre 30 e 60 anos e 67,1% eram mulheres. Confirmamos uma maior recorrência em pacientes com exposição ocupacional ao sol. A ciclosporina A tópica utilizada 10 dias antes e 10 dias após a remoção do pterígio não reduziu significativamente a sua recorrência Conclusão: A ciclosporina A tópica a 0,05% quando utilizada por 10 dias no pré e 10 dias no pós-operatório, não previne ou reduz a recidiva do pterígio primário significativamente.

Humans , Male , Female , Adult , Middle Aged , Young Adult , Pterygium/prevention & control , Cyclosporine/administration & dosage , Conjunctiva/abnormalities , Immunosuppressive Agents/administration & dosage , Ophthalmic Solutions/administration & dosage , Postoperative Care , Recurrence , Surgical Flaps , Preoperative Care , Pterygium/surgery , Pterygium/drug therapy , Prospective Studies , Combined Modality Therapy , Conjunctiva/surgery , Corneal Diseases/drug therapy , Fluorouracil/therapeutic use
Autops. Case Rep ; 9(2): e2019087, Abr.-Jun. 2019. graf, tab
Article in English | LILACS | ID: biblio-1015059


The combination of cisplatin and gemcitabine is the standard first-line treatment of metastatic biliary tract cancer (BTC) patients. The benefit of second-line chemotherapy in these patients is controversial. This study aims to evaluate the activity of FOLFIRI (fluorouracil and irinotecan) after failure to the first-line platinum and gemcitabine-based chemotherapy in metastatic BTC patients. We present a single-institution, retrospective cohort study. Patients with locally advanced or metastatic BTC who progressed after at least one line of chemotherapy, consecutively treated at our Institution between 2007 and 2017 were included. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), clinical benefit rate (CBR) and safety profile of FOLFIRI. Twelve patients were included in the analysis, with a median follow up of 5 months (95% CI 2.77-7.20). The median number of cycles received was 3 (range 1 to 9). Four grade 3 toxicities were recorded; no grade 4 toxicities and no treatment-related deaths occurred. The median PFS was 1.7 months (95% CI; 0.66-2.67), and median OS was 5 months (95% CI; 2.77-7.20). Two patients presented stable disease, providing a CBR of 17%. We concluded that FOLFIRI presented a favorable toxicity profile and a modest activity in metastatic BTC patients who had progressed to platinum and gemcitabine and may be considered in patients who are able to tolerate additional lines of chemotherapy. Immunotherapy and targeted therapies selected according to the tumoral genomic profile are promising alternatives to improve the outcomes of second-line treatment in BTC.

Humans , Biliary Tract Neoplasms/drug therapy , Fluorouracil/therapeutic use , /therapeutic use , Neoplasm Metastasis/drug therapy
Rev. Assoc. Med. Bras. (1992) ; 65(2): 177-182, Feb. 2019. tab
Article in English | LILACS | ID: biblio-990334


SUMMARY OBJECTIVE: To explore the effect of FOLFOX6 chemotherapy on serum vascular endothelial growth factor (VEGF) expression in advanced colorectal cancer patients. METHODS: A retrospective analysis of 81 patients with advanced colorectal cancer who visited our hospital from March 2014 to February 2016 was performed. All the patients were treated with FOLFOX6 chemotherapy. On day 1, patients received oxaliplatin 100 mg/m2 ivgtt (2h), calcium folinate 200 mg/m2 ivgtt (2h), 5 fluorouracil 400 mg/m2 iv bolus and 5 fluorouracil 2500 mg/m2 ivgtt (5h). The treatment course was 2 weeks, and 4 treatment courses were required. The changes in the levels of VEGF and CRP and quality of life before and after 4 courses of chemotherapy were observed and therapeutic effects and adverse reactions after chemotherapy were evaluated. RESULTS: After treatment, the total efficiency of chemotherapy was 82.72% (67/81) with 24 cases in complete remission, 25 cases in partial response, 18 cases in stable disease and 14 cases in progressive disease. The levels of CRP and VEGF after the treatment were significantly lower than those before treatment (5.69±0.77) mg/L vs. (7.99±1.36) mg/L; (443.26±21.55) pg/mL vs. (542.83±20.44) pg/mL] (P<0.05). The KPS grade after treatment was significantly higher than that before treatment (57.84±4.6) point vs. (50.99±3.73) point] (P<0.05). Among them, 3 cases developed a rash, 5 cases experienced hair loss, and 9 cases developed nausea and vomiting. CONCLUSION: FOLFOX6 chemotherapy can decrease serum VEGF expression in patients with advanced colorectal cancer and enhance the curative effect with high safety, which is good for the improvement of patients' survival.

RESUMO OBJETIVO: Explorar o efeito da quimioterapia Folfox6 na expressão do fator de crescimento endotelial vascular sérico (VEGF) em pacientes com câncer colorretal avançado. MÉTODOS: Uma análise retrospectiva de 81 pacientes com câncer colorretal avançado que visitaram nosso hospital de março de 2014 a fevereiro de 2016 foi realizada. Todos os pacientes foram tratados com quimioterapia Folfox6. No dia 1, os doentes receberam oxaliplatina 100 mg / m2 ivgtt (2h), folinato de cálcio 200 mg/m2 ivgtt (2h), 5 fluorouracil 400 mg/m2 iv bolus e 5 fluorouracil 2.500 mg/m2 ivgtt (5h). O curso de tratamento foi de duas semanas e foram necessários quatro cursos de tratamento. Foram observadas as alterações nos níveis de VEGF e CRP e qualidade de vida antes e após quatro cursos de quimioterapia e avaliados os efeitos terapêuticos e reações adversas após a quimioterapia. RESULTADOS: Após o tratamento, a eficácia total da quimioterapia foi de 82,72% (67/81), com 24 casos em remissão completa, 25 casos em resposta parcial, 18 casos em doença estável e 14 casos em doença progressiva. Os níveis de CRP e VEGF após o tratamento foram significativamente inferiores aos do tratamento (5,69 ± 0,77) mg / L vs. (7,99 ± 1,36) mg / L; (443,26 ± 21,55) pg / mL vs. (542,83 ± 20,44) pg / mL] (P < 0,05). O grau de KPS após o tratamento foi significativamente maior do que antes do tratamento (57,84 ± 4,6 pontos) vs. (50,99 ± 3,73 pontos)] (P < 0,05). Entre eles, três casos desenvolveram erupção cutânea, cinco casos sofreram perda de cabelo e nove casos desenvolveram náuseas e vômitos. CONCLUSÃO: A quimioterapia Folfox6 pode, obviamente, diminuir a expressão de VEGF no soro em pacientes com câncer colorretal avançado e melhorar o efeito curativo com alta segurança, o que é bom para a melhoria da sobrevivência dos pacientes.

Humans , Male , Female , Adult , Aged , Colorectal Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Vascular Endothelial Growth Factor A/blood , Antineoplastic Agents/administration & dosage , Organoplatinum Compounds/administration & dosage , Colorectal Neoplasms/blood , Leucovorin/administration & dosage , Retrospective Studies , Disease-Free Survival , Fluorouracil/administration & dosage , Middle Aged , Neoplasm Staging
Article in English | WPRIM | ID: wpr-776636


OBJECTIVE@#To investigate the effects of ethanol extract of Patrinia scabiosaefolia (EEPS) on chemo-resistance of colorectal cancer cells (CRC) and explore the possible molecular mechanisms.@*METHODS@#5-fluorouracil (5-FU)-resistant human colorectal carcinoma cell line (HCT-8/5-FU) and its parental cells HCT-8 were treated with EEPS (0, 0.25, 0.50, 1 or 2 mg/mL), or 5-FU (0, 100, 200, 400, 800 or 1600 μmol/L). The 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was performed to evaluate the cell viability. Cell density was observed by phase-contrast microscope, cell counting and colony formation assay were used to determine the cell proliferation of HCT-8/5-FU cells treated with 0, 0.5, 1 or 2 mg/mL EEPS. Cell apoptosis was determined by Hoechst staining. Western-blot was performed to detect the phosphorylation of AKT as well as the protein expression level of B-cell CLL/lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax).@*RESULTS@#Compared with HCT-8 cells, MTT assay results indicated that HCT-8/5-FU cells were resistant to 5-FU treatment (P0.05). Moreover, compared with untreated HCT-8/5-FU cells, 1 and 2 mg/mL of EEPS treatment significantly reduced cell density, cell number, inhibited cell survival (P<0.05), and induced apoptosis in HCT-8/5-FU cells. Furthermore, 1 and 2 mg/mL of EEPS significantly decreased the phosphorylation level of p-AKT and Bcl-2 protein expression, and increased the expression of Bax protein (P<0.05).@*CONCLUSION@#EEPS is a promising therapeutic agent that may overcome chemo-resistance in cancer cells, likely through suppression of the AKT pathway and promotion of cancer cell apoptosis.

Apoptosis , Cell Line, Tumor , Cell Proliferation , Cell Survival , Colorectal Neoplasms , Drug Therapy , Pathology , Drug Resistance, Neoplasm , Fluorouracil , Pharmacology , Therapeutic Uses , Humans , Patrinia , Chemistry , Phosphorylation , Proto-Oncogene Proteins c-akt , Metabolism , Signal Transduction , Tumor Stem Cell Assay , bcl-2-Associated X Protein , Metabolism